The aminothiol redox status in haemodialysis patients does not improve with folate therapy

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 69, Issue 2, 2009, Pages 265-271

  Apeland, T ^a   Kristensen, O ^a   Mansoor, M A ^b  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF AGDER   (Norway)

Author keywords

Cysteine; Cysteinylglycine; Homocysteine; Homocystine; Leucovorin; Oxidative stress; Renal dialysis

Indexed keywords

AMINOTHIOL; CYSTEINE; CYSTEINYLGLYCINE; FOLIC ACID; FOLINATE CALCIUM; FOLINIC ACID; HOMOCYSTEINE; THIOL DERIVATIVE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERHOMOCYSTEINEMIA; MAINTENANCE THERAPY; MALE; OXIDATION REDUCTION REACTION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; TREATMENT DURATION; AGED; BLOOD; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

AGED; FEMALE; FOLIC ACID; HUMANS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; RENAL DIALYSIS; SULFHYDRYL COMPOUNDS;

EID: 65649152416     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510802521143     Document Type: Article

References (41)

1. Raine AE, Margreiter R, Brunner FP, Ehrich JH, Geerlings W, Landais P, Loirat C, Mallick NP, Selwood NH, Tufveson G, et al. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 1992;7:7-35.
2. Bostom AG, Culleton BF. Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol 1999;10:891-900.
3. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524-38.
4. Jacobsen DW. Hyperhomocysteinemia and oxidative stress: time for a reality check? Arterioscler Thromb Vasc Biol 2000;20:1182-4.
5. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003;91:7A-11A.
6. Moustapha A, Gupta A, Robinson K, Arheart K, Jacobsen DW, Schreiber MJ, Dennis VW. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Kidney Int 1999;55:1470-5.
7. Ducloux D, Klein A, Kazory A, Devillard N, Chalopin JM. Impact of malnutrition-inflammation on the association between homocysteine and mortality. Kidney Int 2006;69:331-5.
8. Van den Berg M, Boers GH, Franken DG, Blom HJ, Van Kamp GJ, Jakobs C, Rauwerda JA, Kluft C, Stehouwert CD. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995;25:176-81.
9. Chao CL, Kuo TL, Lee YT. Effects of methionine-induced hyperhomocysteinemia on endothelium-dependent vasodilation and oxidative status in healthy adults. Circulation 2000;101:485-90.
10. Ueland PM, Refsum H, Beresford SA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000;72:324-32.
11. Chambers JC, Ueland PM, Wright M, Dore CJ, Refsum H, Kooner JS. Investigation of relationship between reduced, oxidized, and proteinbound homocysteine and vascular endothelial function in healthy human subjects. Circ Res 2001;89:187-92.
12. Li H, Lewis A, Brodsky S, Rieger R, Iden C, Goligorsky MS. Homocysteine induces 3-hydroxy-3-methylglutaryl coenzyme a reductase in vascular endothelial cells: a mechanism for development of atherosclerosis? Circulation 2002;105:1037-43.
13. Weiss N. Mechanisms of increased vascular oxidant stress in hyperhomocys-teinemia and its impact on endothelial function. Curr Drug Metab 2005;6:27-36.
14. Ueland PM. Homocysteine species as components of plasma redox thiol status. Clin Chem 1995;41:340-2.
15. Apeland T, Mansoor MA, Seljeflot I, Bronstad I, Goransson L, Strandjord RE. Homocysteine, malondialdehyde and endothelial markers in dialysis patients during low-dose folinic acid therapy. J Intern Med 2002;252:456-64.
16. Mansoor MA, Svardal AM, Schneede J, Ueland PM. Dynamic relation between reduced, oxidized, and protein-bound homocysteine and other thiol components in plasma during methionine loading in healthy men. Clin Chem 1992;38:1316-21.
17. Mansoor MA, Svardal AM, Ueland PM. Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine, and glutathione in human plasma. Anal Biochem 1992;200:218-29.
18. Ueland PM, Mansoor MA, Guttormsen AB, Muller F, Aukrust P, Refsum H, Svardal AM. Reduced, oxidized and protein-bound forms of homocysteine and other aminothiols in plasma comprise the redox thiol status - a possible element of the extracellular antioxidant defense system. J Nutr 1996;126:1281S-4S.
19. Andersson A, Lindgren A, Arnadottir M, Prytz H, Hultberg B. Thiols as a measure of plasma redox status in healthy subjects and in patients with renal or liver failure. Clin Chem 1999;45:1084-6.
20. Di Giuseppe D, Di Simplicio P, Capecchi PL, Lazzerini PE, Pasini FL. Alteration in the redox state of plasma in heart-transplant patients with moderate hyperhomocysteinemia. J Lab Clin Med 2003;142:21-8.
21. Hultberg B, Andersson A, Arnadottir M. Reduced, free and total fractions of homocysteine and other thiol compounds in plasma from patients with renal failure. Nephron 1995;70:62-7.
22. Van Tits L, De Graaf J, Hak-Lemmers H, Bredie S, Demacker P, Holvoet P, Stalenhoef A. Increased levels of low-density lipoprotein oxidation in patients with familial hypercholester-olemia and in end-stage renal disease patients on hemodialysis. Lab Invest 2003;83:13-21.
23. Hasselwander O, Young IS. Oxidative stress in chronic renal failure. Free Radic Res 1998;29:1-11.
24. Himmelfarb J, McMenamin E, McMonagle E. Plasma aminothiol oxidation in chronic hemodialysis patients. Kidney Int 2002;61:705-16.
25. Palleschi S, De Angelis S, Rossi B, Diana L, Papa V, Severini G, Splendiani G. Homocysteinemia correlates with plasma thiol redox status in patients with end-stage renal disease. Nephron Clin Pract 2008;108:c106-12.
26. Cianciolo G, La Manna G, Coli L, Donati G, D'Addio F, Persici E, Comai G, Wratten M, Dormi A, Mantovani V, Grossi G, Stefoni S. 5-Methyltetrahydrofolate administration is associated with prolonged survival and reduced inflammation in ESRD patients. Am J Nephrol 2008;28:941-8.
27. Zou CG, Banerjee R. Homocysteine and redox signaling. Antioxid Redox Signal 2005;7:547-59.
28. Mansoor MA, Bergmark C, Svardal AM, Lonning PE, Ueland PM. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with earlyonset peripheral vascular disease. Homocysteine and peripheral vascular disease. Arterioscler Thromb Vasc Biol 1995;15:232-40.
29. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 1994;344:721-4.
30. Ghezzi P, Bonetto V. Redox proteomics: identification of oxidatively modified proteins. Proteomics 2003;3:1145-53.
31. Apeland T, Froyland ES, Kristensen O, Strandjord RE, Mansoor MA. Drug-induced pertubation of the aminothiol redox-status in patients with epilepsy: Improvement by B-vitamins. Epilepsy Res 2008. In press; In press.
32. Vianna AC, Mocelin AJ, Matsuo T, Morais-Filho D, Largura A, Delfino VA, Soares AE, Matni AM. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events. Hemodial Int 2007;11:210-16.
33. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. J Am Med Assoc 2007;298:1163-70.
34. Suliman ME, Filho JC, Barany P, Anderstam B, Lindholm B, Bergstrom J. Effects of methionine loading on plasma and erythrocyte sulphur amino acids and sulph-hydryls before and after co-factor supplementation in haemodialysis patients. Nephrol Dial Transplant 2001;16:102-10.
35. Righetti M, Serbelloni P, Milani S, Ferrario G. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif 2006;24:379-86.
36. Clarke R, Lewington S, Sherliker P, Armitage J. Effects of B-vitamins on plasma homocysteine concentrations and on risk of cardiovascular disease and dementia. Curr Opin Clin Nutr Metab Care 2007;10:32-9.
37. Blom HJ, De Vriese AS. Why are homocysteine levels increased in kidney failure? A metabolic approach. J Lab Clin Med 2002;139:262-8.
38. Guttormsen AB, Ueland PM, Svarstad E, Refsum H. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 1997;52:495-502.
39. Yango A, Shemin D, Hsu N, Jacques PF, Dworkin L, Selhub J, Bostom AG. Rapid communication: L-folinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Kidney Int 2001;59:324-7.
40. Bergesio F, Monzani G, Guasparini A, Ciuti R, Gallucci M, Cristofano C, Castrignano E, Cupisti A, Barsotti G, Marcucci R, Abbate R, Bandini S, Gallo M, Tosi PL, Salvadori M. Cardiovascular risk factors in severe chronic renal failure: the role of dietary treatment. Clin Nephrol 2005;64:103-12.
41. Siems W, Quast S, Carluccio F, Wiswedel I, Hirsch D, Augustin W, Kraemer K, Hampl H, Sommerburg O. Oxidative stress in cardio renal anemia syndrome: correlations and therapeutic possibilities. Clin Nephrol 2003;60 Suppl 1:S22-30.